Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of ixazomib-based induction regimens followed by ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma
2014-004859-31Phase 2Completed
- Sponsor
- Department of Molecular Biotechnology and Health Sciences, University of Turin
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ixazomib in multiple myeloma (MM) (4 arms), sponsored by Department of Molecular Biotechnology and Health Sciences, University of Turin. Primary endpoint: Progression-free survival at 2 years from diagnosis. Started Dec 2014; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-004859-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004859-31.